Biotech Bay
Filter News
Found 55,167 articles
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more. -
3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by Boehringer Ingelheim.
-
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. What are the unique benefits your life sciences employer offers?
-
Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019
2/22/2019
At the Type B meeting, Aradigm presented the results of the Third Party Evaluation (TPE) completed in December 2019 that addressed the clinical issue raised by the FDA in the complete response letter (CRL) received in January 2018.
-
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
-
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
-
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
-
Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
2/21/2019
Rainier Therapeutics, Inc. announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m. ET at the Lotte New York Palace in New York City.
-
MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation
2/21/2019
MPM Capital, a life-sciences venture capital firm investing in early-stage therapeutics companies, announced the closing of its seventh venture fund, BioVentures 2018.
-
Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
2/21/2019
DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients
-
Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
2/21/2019
Audentes Therapeutics, Inc., will host a conference call and webcast to report its fourth quarter and full year 2018 financial results and provide a corporate update on Wednesday, February 27, 2019.
-
DURECT Corporation to Participate in the Berenberg NASH Day
2/21/2019
DURECT Corporation today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg's New York City offices.
-
Dr. Ross Jaffe, MD Joins NEA As Venture Advisor
2/21/2019
Prolific Medical Technology Investor and Seasoned Board Member Brings Experience to Global Venture Capital Firm and Portfolio Companies
-
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
2/21/2019
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Leerink Partners 8th Annual Global Healthcare Conference in New York.
-
Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D.
2/21/2019
Anixa Biosciences, Inc. announced it has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich, M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response.
-
Guiding Principles on Ethics in Digital Health Produced During a Seminar at Stanford Libraries
2/21/2019
Proteus Digital Health and more than 30 representatives from technology, pharmaceutical, healthcare, public policy, law and bioethics convene at Stanford to address the responsibility around management of personal data.
-
iSchemaView’s RAPID™ Approved for Use in Brazil
2/21/2019
iSchemaView Expands RAPID’s South American Footprint by Bringing Brazil the Only Clinically Validated, Next-Generation Imaging Platform for Assessing Ischemic Stroke
-
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
2/21/2019
Amgen (NASDAQ: AMGN),Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
2/21/2019
Aimmune Therapeutics, Inc. announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
-
Kedalion Therapeutics Broadens Leadership Team and Expands Scientific Advisory Board
2/21/2019
Kedalion today announced the hiring of Casey Dougan to its management team as Vice President of Corporate Development, as well as the addition of Richard L. Lindstrom, M.D., and John Berdahl, M.D., to its Scientific Advisory Board.